tablets Preneliya® are applied at the following indications:

• Arterial hypertension.
• Heart failure.
• Prevention of a repeated stroke at patients with cerebrovascular diseases.
• Prevention of cardiovascular complications at patients with documentary confirmed stable coronary heart disease. Long-term treatment reduces risk of developing of a myocardial infarction and heart failure.

Structure

Active ingredient: perindoprit.

1 the tablet Preneliya®, 4 mg supports a perindopril of a tertbutilamin - 4.0 mg that corresponds to 3.338 mg of a perindopril.

1 the tablet Preneliya®, 8 mg supports a perindopril of a tertbutilamin - 8.0 mg that corresponds to 6.676 mg of a perindopril.

Excipients: lactose monohydrate, cellulose microcrystalline silicon dioxide colloidal stearate of magnesium.

Contraindication

• Hypersensitivity to a perindopril or to any of excipients, or to any other APF inhibitor;
• a Quincke's disease in the anamnesis after APF inhibitor use;
• idiopathic or hereditary Quincke's disease;
• pregnant women, women who are going to become pregnant and women of childbearing age, do not apply adequate contraceptives;
simultaneous use with sakubitrit
• / valsartany for increased risk of developing a Quincke's disease;
• simultaneous use with the medicaments containing active ingredient aliskiren for patients with diabetes or a renal failure (glomerular filtration rate <60 ml/min. / 1.73 m ² );
• extracorporal treatment which leads to contact of blood with negatively charged surfaces;
• considerable bilateral stenosis of renal arteries or stenosis of an artery of the only kidney.

Route of administration

For oral administration.

recommends to take the Pill 1 time a day in the morning before food.

Recommended initial dose makes 4 mg of 1 times a day in the morning.

Feature of use

It was reported about exceptional cases of developing of a Quincke's disease of the face, extremities, lips, mucous membranes, language, a glottis and/or throat at patients, at use of APF inhibitors, including perindoprit a tertbutilamin.

Medicine it is contraindicated to the pregnant women or women planning pregnancy to apply

.

Children

children can use Drug aged from 18 years.

Drivers

It is contraindicated.

Overdose

Information on overdose insufficiently. The symptoms connected with overdose of APF inhibitors can be the following: arterial hypotension, circulator shock, disturbance of electrolytic balance, renal failure, hyperventilation, tachycardia, cardiopalmus, bradycardia, dizziness, alarm, cough and so forth.

Side reactions

Most frequent side reactions which are observed at use of a perindopril are: cough, dizziness, headache, asthenia, gastrointestinal disorders (abdominal pain, nausea and dyspepsia).

Most serious side reactions: reactions of hypersensitivity (Quincke's disease), a renal failure (at patients from high risk), pancreatitis, blood disturbances (pancytopenia, an agranulocytosis and thrombocytopenia).

At safety assessment at prolonged use the patients with heart failure have heavy side reactions with the largest frequency there were stenocardia and orthostatic hypotension.

Interaction

Some medicines or therapeutic classes of medicines can cause a hyperpotassemia, namely: aliskiren, potassium salts, kaliysberegayushchy diuretics, APF inhibitors, antagonists of receptors of angiotensin II, non-steroidal anti-inflammatory medicaments (NPVS), heparin, immunosuppressors, such as cyclosporine or takrolimus, Trimethoprimum. The concomitant use of the specified medicines increases risk of emergence of a hyperpotassemia.

Storage conditions

In original packing at a temperature not above 25 °C. To store out of children's reach.

Expiration date - 1 year.